Does routine intravenous glucagon administration facilitate colonoscopy? A randomized trial.

Cutler CS, Rex DK, Hawes RH, Lehman GA

Gastrointestinal endoscopy1 Oct 1995Cited by 24 (Europe PMC)

PMID8536905DOI10.1016/s0016-5107(95)70135-4PepBankPUB-08536905

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In sedated colonoscopy patients, mean insertion time was identical with glucagon and placebo at 5.07 min.
In plain wordsIn sedated colonoscopy patients, insertion time was identical with glucagon and placebo.
Peptide
Glucagon
Outcome
No significant changeInsertion time in Study 2
Study
n = 90
Comparator
Placebo
Outcome group
Colonoscopy Performance · Gastrointestinal
Studied dose
1 mg · intravenousAs given in this study (human).
Measurements
Insertion time
5.07 min
both groups
Source sentences
Summary
Mean insertion time in Study 2 (5.07 min) was identical between groups.
1 context sentence(design, population, supporting numbers)
Summary · context
In a second study (Study 2) 90 sedated patients undergoing colonoscopy were randomized to receive 1 mg glucagon (n = 46) or placebo (n = 44), intravenously, just before colonoscope insertion.
Report a problemFND-0853690502
02HumanRandomized controlled trialEfficacy outcome
In Study 2 colonoscopy patients, spasm scores did not differ between glucagon and placebo.
In plain wordsIn Study 2 colonoscopy patients, spasm scores did not differ between glucagon and placebo.
Peptide
Glucagon
Outcome
No significant changeSpasm scores in Study 2
Study
n = 90
Comparator
Placebo
Outcome group
Colonoscopy Performance · Gastrointestinal
Studied dose
1 mg · intravenousAs given in this study (human).
Source sentences
Summary
Spasm scores and colonoscopy yield did not differ between glucagon and placebo in either study.
1 context sentence(design, population, supporting numbers)
Summary · context
In a second study (Study 2) 90 sedated patients undergoing colonoscopy were randomized to receive 1 mg glucagon (n = 46) or placebo (n = 44), intravenously, just before colonoscope insertion.
Report a problemFND-0853690504
03HumanRandomized controlled trialEfficacy outcome
In Study 2 colonoscopy patients, colonoscopy yield did not differ between glucagon and placebo.
In plain wordsIn Study 2 colonoscopy patients, examination yield did not differ between glucagon and placebo.
Peptide
Glucagon
Outcome
No significant changeColonoscopy yield in Study 2
Study
n = 90
Comparator
Placebo
Outcome group
Colonoscopy Performance · Gastrointestinal
Studied dose
1 mg · intravenousAs given in this study (human).
Source sentences
Summary
Spasm scores and colonoscopy yield did not differ between glucagon and placebo in either study.
1 context sentence(design, population, supporting numbers)
Summary · context
In a second study (Study 2) 90 sedated patients undergoing colonoscopy were randomized to receive 1 mg glucagon (n = 46) or placebo (n = 44), intravenously, just before colonoscope insertion.
Report a problemFND-0853690506
04HumanRandomized controlled trialEfficacy outcome
In colonoscopy patients, withdrawal time was similar with glucagon and placebo: 6.85 versus 6.92 min.
In plain wordsIn colonoscopy patients, withdrawal time was similar with glucagon and placebo.
Peptide
Glucagon
Outcome
No significant changeWithdrawal time in Study 1
Study
n = 80
Comparator
Placebo
Outcome group
Colonoscopy Performance · Gastrointestinal
Studied dose
1 mg · intravenousAs given in this study (human).
Measurements
Withdrawal time
6.85 min
glucagon
Withdrawal time
6.92 min
placebo
Source sentences
Summary
Mean withdrawal time in Study 1 was similar in those receiving glucagon (6.85 min) and in those receiving placebo (6.92 min).
1 context sentence(design, population, supporting numbers)
Summary · context
In one study (Study 1), 80 consecutive patients were randomized after cecal intubation to receive 1 mg glucagon (n = 41) or placebo (n = 39), intravenously, in double-blind fashion.
Report a problemFND-0853690501
05HumanRandomized controlled trialEfficacy outcome
In Study 1 colonoscopy patients, spasm scores did not differ between glucagon and placebo.
In plain wordsIn Study 1 colonoscopy patients, spasm scores did not differ between glucagon and placebo.
Peptide
Glucagon
Outcome
No significant changeSpasm scores in Study 1
Study
n = 80
Comparator
Placebo
Outcome group
Colonoscopy Performance · Gastrointestinal
Studied dose
1 mg · intravenousAs given in this study (human).
Source sentences
Summary
Spasm scores and colonoscopy yield did not differ between glucagon and placebo in either study.
1 context sentence(design, population, supporting numbers)
Summary · context
In one study (Study 1), 80 consecutive patients were randomized after cecal intubation to receive 1 mg glucagon (n = 41) or placebo (n = 39), intravenously, in double-blind fashion.
Report a problemFND-0853690503
06HumanRandomized controlled trialEfficacy outcome
In Study 1 colonoscopy patients, colonoscopy yield did not differ between glucagon and placebo.
In plain wordsIn Study 1 colonoscopy patients, examination yield did not differ between glucagon and placebo.
Peptide
Glucagon
Outcome
No significant changeColonoscopy yield in Study 1
Study
n = 80
Comparator
Placebo
Outcome group
Colonoscopy Performance · Gastrointestinal
Studied dose
1 mg · intravenousAs given in this study (human).
Source sentences
Summary
Spasm scores and colonoscopy yield did not differ between glucagon and placebo in either study.
1 context sentence(design, population, supporting numbers)
Summary · context
In one study (Study 1), 80 consecutive patients were randomized after cecal intubation to receive 1 mg glucagon (n = 41) or placebo (n = 39), intravenously, in double-blind fashion.
Report a problemFND-0853690505
07HumanRandomized controlled trialSafety outcome
In Study 1 colonoscopy patients, there was a trend toward more side effects (nausea and vomiting) with glucagon than with placebo.
In plain wordsIn Study 1 colonoscopy patients, there was a trend toward more side effects (nausea and vomiting) with glucagon than with placebo.
Peptide
Glucagon
Outcome
IncreaseSide effects (nausea and vomiting) in Study 1
Study
n = 80
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1 mg · intravenousAs given in this study (human).
Source sentences
Summary
There was a trend toward more side effects (nausea and vomiting) with glucagon in Study 1.
1 context sentence(design, population, supporting numbers)
Summary · context
In one study (Study 1), 80 consecutive patients were randomized after cecal intubation to receive 1 mg glucagon (n = 41) or placebo (n = 39), intravenously, in double-blind fashion.
Report a problemFND-0853690507
08HumanRandomized controlled trialEfficacy outcome
In patients with diverticulosis, glucagon did not facilitate colonoscope insertion compared with placebo.
In plain wordsIn patients with diverticulosis, glucagon did not ease colonoscope insertion compared with placebo.
Peptide
Glucagon
Outcome
No significant changeInsertion in diverticulosis subset
Study
n: not reported in source
Comparator
Placebo
Outcome group
Colonoscopy Performance · Gastrointestinal
Studied dose
1 mg · intravenousAs given in this study (human).
Source sentences
Summary
Glucagon did not facilitate insertion or withdrawal in the subset of patients with diverticulosis.
1 context sentence(design, population, supporting numbers)
Summary · context
In a second study (Study 2) 90 sedated patients undergoing colonoscopy were randomized to receive 1 mg glucagon (n = 46) or placebo (n = 44), intravenously, just before colonoscope insertion.
Report a problemFND-0853690509
09HumanRandomized controlled trialEfficacy outcome
In patients with diverticulosis, glucagon did not facilitate colonoscope withdrawal compared with placebo.
In plain wordsIn patients with diverticulosis, glucagon did not ease colonoscope withdrawal compared with placebo.
Peptide
Glucagon
Outcome
No significant changeWithdrawal in diverticulosis subset
Study
n: not reported in source
Comparator
Placebo
Outcome group
Colonoscopy Performance · Gastrointestinal
Studied dose
1 mg · intravenousAs given in this study (human).
Source sentences
Summary
Glucagon did not facilitate insertion or withdrawal in the subset of patients with diverticulosis.
1 context sentence(design, population, supporting numbers)
Summary · context
In one study (Study 1), 80 consecutive patients were randomized after cecal intubation to receive 1 mg glucagon (n = 41) or placebo (n = 39), intravenously, in double-blind fashion.
Report a problemFND-0853690510

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.